TY - JOUR
T1 - The Collaborative Ocular Tuberculosis Study (COTS)-1
T2 - A Multinational Description of the Spectrum of Choroidal Involvement in 245 Patients with Tubercular Uveitis
AU - Agrawal, Rupesh
AU - Gunasekeran, Dinesh Visva
AU - Agarwal, Aniruddha
AU - Carreño, Ester
AU - Aggarwal, Kanika
AU - Gupta, Bhaskar
AU - Raje, Dhananjay
AU - Murthy, Somasheila I.
AU - Westcott, Mark
AU - Chee, Soon Phaik
AU - McCluskey, Peter
AU - Ling, Ho Su
AU - Teoh, Stephen
AU - Cimino, Luca
AU - Biswas, Jyotirmay
AU - Narain, Shishir
AU - Agarwal, Manisha
AU - Mahendradas, Padmamalini
AU - Khairallah, Moncef
AU - Jones, Nicholas
AU - Tugal-Tutkun, Ilknur
AU - Babu, Kalpana
AU - Basu, Soumayava
AU - Lee, Richard
AU - Al-Dhibi, Hassan
AU - Bodaghi, Bahram
AU - Invernizzi, Alessandro
AU - Goldstein, Debra A.
AU - Herbort, Carl P.
AU - Barisani-Asenbauer, Talin
AU - González-López, Julio J.
AU - Androudi, Sofia
AU - Bansal, Reema
AU - Moharana, Bruttendu
AU - Mahajan, Sarakshi
AU - Esposti, Simona
AU - Tasiopoulou, Anastasia
AU - Nadarajah, Sengal
AU - Agarwal, Mamta
AU - Abraham, Sharanya
AU - Vala, Ruchi
AU - Lord, Joanne
AU - Singh, Ramandeep
AU - Sharma, Aman
AU - Sharma, Kusum
AU - Zierhut, Manfred
AU - Kon, Onn Min
AU - Kempen, John
AU - Cunningham, Emmett T.
AU - Rousselot, Andres
AU - Nguyen, Quan Dong
AU - Pavesio, Carlos
AU - Gupta, Vishali
N1 - Publisher Copyright:
©, Taylor & Francis Group, LLC.
PY - 2020
Y1 - 2020
N2 - Purpose: To contribute a global description of the spectrum of choroidal involvement in tubercular uveitis (TBU). Methods: Retrospective cohort study of TBU patients with choroidal involvement from 25 centers between January 2004 and December 2014. Medical records of patients with a minimum follow-up of 1 year were reviewed. Results: 245 patients were included. The phenotypic variations included serpiginous-like choroiditis (SLC) (46%), tuberculoma (13.5%), multifocal choroiditis (MFC) (9.4%), ampiginous choroiditis (9%), among others. 219 patients were treated with anti-tubercular therapy (ATT) (n = 219/245, 89.38%), 229 patients with steroids (n = 229/245, 93.47%) and 28 patients with immunosuppressive agents (n = 28/245, 11.42%). Treatment failure was noted in 38 patients (n = 38/245, 15.5%). Patients with SLC and ampiginous choroiditis appeared to have superior outcomes on survival analysis (p = 0.06). Conclusion: This study provides a comprehensive description of choroidal involvement in TBU. Patients with SLC and ampiginous choroiditis may have better clinical outcomes.
AB - Purpose: To contribute a global description of the spectrum of choroidal involvement in tubercular uveitis (TBU). Methods: Retrospective cohort study of TBU patients with choroidal involvement from 25 centers between January 2004 and December 2014. Medical records of patients with a minimum follow-up of 1 year were reviewed. Results: 245 patients were included. The phenotypic variations included serpiginous-like choroiditis (SLC) (46%), tuberculoma (13.5%), multifocal choroiditis (MFC) (9.4%), ampiginous choroiditis (9%), among others. 219 patients were treated with anti-tubercular therapy (ATT) (n = 219/245, 89.38%), 229 patients with steroids (n = 229/245, 93.47%) and 28 patients with immunosuppressive agents (n = 28/245, 11.42%). Treatment failure was noted in 38 patients (n = 38/245, 15.5%). Patients with SLC and ampiginous choroiditis appeared to have superior outcomes on survival analysis (p = 0.06). Conclusion: This study provides a comprehensive description of choroidal involvement in TBU. Patients with SLC and ampiginous choroiditis may have better clinical outcomes.
KW - Anti-tubercular therapy
KW - choroiditis
KW - ocular
KW - tuberculosis
KW - uveitis
UR - http://www.scopus.com/inward/record.url?scp=85053279767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053279767&partnerID=8YFLogxK
U2 - 10.1080/09273948.2018.1489061
DO - 10.1080/09273948.2018.1489061
M3 - Article
C2 - 30156979
AN - SCOPUS:85053279767
SN - 0927-3948
VL - 28
SP - 38
EP - 48
JO - Ocular Immunology and Inflammation
JF - Ocular Immunology and Inflammation
IS - sup1
ER -